Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of T2DM~* On a stable dose of insulin as defined by the protocol~* On a stable does of metformin (if applicable) as defined by the protocol~* Age 18 to 80 years~* HbA1c of 7.5 to 11.0%~* Body Mass Index (BMI) 22 to 40 kg/m2~Exclusion Criteria:~* Type 1 diabetes~* Short-acting or rapid-acting insulin~* Pregnancy or lactation~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular complications~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).